Markus Hansson

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach et al. · New England Journal of Medicine · 2015 · 1.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Philippe Moreau, Tamás Masszi, Norbert Grząśko et al. · New England Journal of Medicine · 2016 · 1.1K citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 384 citations · Full text

Medicine, Hematology, Oncology +17

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Shaji Kumar, Meletios Α. Dimopoulos, Efstathios Kastritis et al. · Leukemia · 2017 · 354 citations · Full text

Medicine, Immunology, Oncology +17

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

María‐Victoria Mateos, Shaji Kumar, Meletios Α. Dimopoulos et al. · Blood Cancer Journal · 2020 · 275 citations · Full text

Medicine, Hematology, Oncology +12